Division of Pediatric Hematology/Oncology, Stony Brook University, Stony Brook, New York 11794-8111, USA.
Cancer Invest. 2010 Dec;28(10):1054-62. doi: 10.3109/07357907.2010.512602. Epub 2010 Sep 27.
Epidermal growth factor receptor (EGFR) is a target in head and neck cancer. High EGFR expression and phosphorylated EGFR predicts poor survival in head and neck cancer patients, but does not correlate with advanced stage disease. The aim of this study is to determine if clinical biological correlates are more accurate when different aspects of EGFR are evaluated in combination. We analyzed the EGFR phosphorylation, expression, and mutations in 60 primary head and neck tumors. We not only found that head and neck tumors with either truncated or activated EGFR tend to have higher tumor and nodal stage but also discovered two novel EGFR truncations.
表皮生长因子受体（EGFR）是头颈部癌症的一个靶点。高 EGFR 表达和磷酸化 EGFR 预示着头颈部癌症患者的预后不良，但与晚期疾病无关。本研究旨在确定在评估 EGFR 的不同方面时，临床生物学相关性是否更准确。我们分析了 60 例原发性头颈部肿瘤的 EGFR 磷酸化、表达和突变。我们不仅发现具有截断或激活 EGFR 的头颈部肿瘤往往具有更高的肿瘤和淋巴结分期，而且还发现了两种新的 EGFR 截断。
